drugset / Trial / NCT00408239

Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement

NCT00408239

Phase 2 Completed 367 enrolled Astellas Pharma Inc
RandomizedParallel-groupOpen-labelPrevention

Summary

Evaluate the safety and tolerability of escalating oral doses of YM150 in patients undergoing elective primary total knee replacement surgery

Timeline

Start
2006-12
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Enoxaparin sodium Other / unclassified Subcutaneous
Subject darexaban Small molecule Oral